0 Items
Select Page

Giardia

Giardia lamblia is an anaerobic, flagellated eukaryotic protozoan and member of the Hexamitidae family of protozoa. Giardia lamblia infects and colonises the small intestine of humans and mammals, causing a globally-common diarrheal disease, known as giardiasis.

The Native Antigen Company offers Giardia monoclonal antibodies for use in immunoassay development.

Giardia Background

Giardia lamblia exists in two forms, as a dormant cyst that infects the small intestine and as a trophozoite – a vegetative form that excysts from the cyst. Trophozoites replicate within the intestine causing the symptoms associated with giardiasis. Both cysts and trophozoites are present in contaminated faeces, but trophozoites do not survive for long periods in the environment. G. lamblia cysts are found in soil and water, and on surfaces contaminated by faeces from an infected individual. Giardiasis infection in humans occurs by transmission of dormant G. lamblia cysts via the faecal oral route or through ingestion of contaminated food and water (CDC).

Giardia Antibodies

Our Giardia-specific antibodies are specific to the trophozoite protein of Giardia lamblia. Our Giardia antibodies do not cross react with Campylobacter spp., Clostridium difficile, Cryptosporidium parvum, Entamoeba histolytica, Escherichia coli, Helicobacter pylori, Listeria monocytogenes, Salmonella spp., Shigella spp. or Staphylococcus aureus.

We also have two monoclonal antibodies available, which may be used as pairs in immunoassay development.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Diagnosing HIV in resource-limited settings

In this blog, we discuss the need for improved point-of-care (PoC) diagnostics for HIV and present the virus's cellular mechanism to illustrate our new range of HIV antigens and antibodies. HIV in the developed world On June 5th 1981 in Los Angeles, California, 5...

Our Product Pipeline

If you’ve been following us on social media recently, you might have noticed that we’ve been releasing a lot of new antigens and antibodies. In this blog, we explain how we use the WHO R&D Blueprint to guide our product development and present some highlights from...

From Outbreak to Epidemic: A Short History of The Ebola Virus

In the first of a two-part series, we discuss the history of the Ebola virus up to the ongoing outbreak in the Democratic Republic of Congo, and why this disease has been so challenging to fight. The 2014/15 epidemic In the summer of 2014, the world watched as the...

ELISA Formats for Infectious Disease Diagnostics

The field of diagnostics is rapidly developing, yet ELISA and PCR methods remain the most commonly used techniques in the diagnosis of bacterial and viral infections. In this blog, we discuss the advantages of using serological methods over molecular, PCR-based...

The world’s most extensive range of NS1-specific antibodies for flavivirus research

The Native Antigen Company first gained prominence in 2016, when it developed highly pure Zika virus NS1 protein during the 2015/2016 epidemic. Since then, the company has developed an extensive range of highly specific antigens, antibodies and immunoassays for...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

8 + 4 =

Live Customer Feedback

Join our mailing list

* indicates required